Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $6.01
Previous CloseN/A
Volume2.07M
Average Volume (3M)471.96K
Market Cap
$87.24M
Enterprise Value$65.79M
Total Cash (Recent Filing)$2.91M
Total Debt (Recent Filing)$10.23M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Nov 17, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding23,769,901
10 Day Avg. Volume465,695
30 Day Avg. Volume471,964
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue16.45K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$33.00Price Target Upside821.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Collaborative EffortsThere are binding agreements or letters of intent with institutions such as Kadima Neuroscience Institute, Dura Medical, and Neurospa, indicating strong collaborative efforts to enhance the treatment landscape.
Cost SavingsThe FDA waived the filing fee for the NRX-100 NDA, resulting in direct savings of a few million dollars.
Drug Application And ApprovalThe FDA granted a Suitability Petition for KETAFREE, allowing it to be sold in single-patient vials, which could reduce waste and create a distinct product with differential pricing.
Bears Say
Financial PerformanceNRXP reported a net loss of $17.6M, primarily from fair value accounting measurements.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.10 and its highest was $6.01 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $87.24M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Nov 17, 2025 which is in 38 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Aug 18, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.83.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 23,769,901 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -9.42%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (821.79% Upside)
$33.00 (821.79% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 30.4%
Last 30 Days ▲ 30.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.89%
12-Months-Change
Fundamentals
Return on Equity
108.28%
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals (NRXP) is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of central nervous system disorders and other critical health conditions. The company operates in the healthcare sector with a particular emphasis on drug development for serious mental illnesses, respiratory diseases, and other critical care indications. Its core products include investigational drugs designed to offer new treatment options for patients with severe mental health disorders and life-threatening pulmonary diseases.
NRXP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development, financial management, and strategic partnerships, with a strong focus on advancing key drug applications and developing the Hope Therapeutics network. Despite increased net losses and regulatory challenges, the company's strategic moves and financial improvements suggest a positive outlook.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$33.00
▲(821.79% Upside)
Technical Analysis
Atara Biotherapeutics
―
Reviva Pharmaceuticals Holdings
―
Coeptis Therapeutics Holdings
―
RenovoRx
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
6.38% Insiders
2.40% Mutual Funds
7.93% Other Institutional Investors
80.11% Public Companies and Individual Investors